Skip to content
MarketScale
‹ Back to IndustriesHealthcare

As Cases Increase, Source of E. Coli 0157 Outbreak is Yet to Be Located

More than two weeks after the latest E. coli outbreak began, the CDC is still searching for its source. The areas affected by the outbreak as well as the number of those infected continues to grow, which is driving up concern across all sectors of the industry. No deaths have been reported, but ten of…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

More than two weeks after the latest E. coli outbreak began, the CDC is still searching for its source. The areas affected by the outbreak as well as the number of those infected continues to grow, which is driving up concern across all sectors of the industry. No deaths have been reported, but ten of those infected have developed kidney failure. While investigators have narrowed down their search for a source to the Yuma region of Arizona, there is still quite a bit of work to be done to determine where the strain is coming from. Once they do, they will be able to enact nationwide recalls if necessary.

At time of writing, there are currently 98 people infected across 22 states. To make matters worse, those affected range from 1 year old to as old as 88. While the concern for human life is certainly tantamount, the economic effect outbreaks of foodborne illnesses and subsequent recalls can have can also be devastating.

When peanut butter was recalled due to a salmonella outbreak, big name brands certainly took a hit. But for Dough-to-go, a small cookie dough business in Seattle, the impact was ruinous. Not only was the company left with $7000 in reimbursement costs to their customers, but they had 2500 pounds of peanut butter in stock that was unusable. While that number may not be as high as what nationwide companies were faced with, their recovery was manageable while it was devastating to the small business.

“We’re the victim, too,” Dough-to-Go owner Betsy Sanders told local publication Seattle PI at the time. “We’ve done nothing wrong and we’re doing everything we can to make sure everyone’s safe.”

From shipping distributors to producers to mom and pop shops, the economic effect of foodborne illness is significant. It is estimated that E.coli and other illnesses costs the food industry $55.5 billion annually. When margins for farmers, restaurant owners and grocery stores are already razor thin, this large of a hit is difficult to swallow.

In this instance, even producers from outside Arizona are being affected. Product labels often do not have the growing region of produce listed, meaning all Romaine lettuce on shelves should be avoided. And until the source can be located, the problem will only continue to grow.

According to Michael Doyle, the Director of the University of Georgia’s Center for Food Safety, often the cleaning processes that companies use when cleaning chopped lettuce for bagged salad mixes are ineffective at removing the e. coli bacteria. In an interview with Modern Farmer, Doyle explained that the harvesting process traps the bacteria inside the plant itself, so when the chlorine-wash that distributors use cleans the outside of the plant, the pathogens inside remain untouched.

Investigators are working around the clock to locate the source of the outbreak, and it will only be then that the cost can be estimated, both economic and personal, for this incident. In the meantime, the CDC cautions against buying romaine lettuce and steering towards other substitutes, especially in instances when origin cannot be determined. As e. coli infections take time to set in, symptoms that arise even a week or so after consuming lettuce should be treated seriously.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly has broken ground on a $6.5 billion manufacturing facility in Houston, slated for completion around 2030. While attention has focused on scaling production of Foundayo, its oral GLP-1 treatment, the project also reflects broader U.S. efforts to rebuild domestic pharmaceutical manufacturing and highlights the supply chain challenge of forecasting demand and building capacity years in advance.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain, making it difficult to commit billions to manufacturing capacity years before demand and required output are clear.
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

NextGen Invent’s Deepak Mittal argues for scoped healthcare AI pilots with early governance

NextGen Invent’s Deepak Mittal argues that healthcare AI pilots can begin with a reliable data subset and early governance. His performance figures are vendor claims, not independently verified results.

  • 01Deepak Mittal advocates starting with a defined problem and suitable data rather than waiting for perfect organization-wide data.
  • 02Some performance figures cited in the interview (for example, preparation time and model counts) are company-reported and not independently verified in this article.
  • 03NIST’s voluntary AI Risk Management Framework provides an independent structure for governance and risk evaluation.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512